Reported accuracies were 86% (Random Forest) and 96% (convolutional neural networks), positioning retinal imaging as a candidate scalable tool for underserved populations. AI-powered polarized-light ...

Cross-sectional analysis of the prospective Low Vision Rehabilitation Outcomes Study included 28 US centers and assessed pre/post rehabilitation function using the Activity Inventory general ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

In late 2025, a group of researchers that included Maria Emfietzoglou, MD, and Victor S.M.C. Correa, MD, published a paper titled, “Inner Plexiform Layer Substrata Are Discernible with Commercial OCT ...

Building on prior Ophthalmology Times coverage examining how ophthalmic drug shortages are both more frequent and longer-lasting than the national average, Ian Pitha, MD, PhD, an ophthalmologist at ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Michaelides is professor at UCL Institute of Ophthalmology and Moorfields Eye Hospital, London.

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.